دورية أكاديمية
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
| العنوان: | Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. |
|---|---|
| المؤلفون: | Seaquist ER; University of Minnesota, Minneapolis, Minnesota., Dulude H; Locemia Solutions, Montreal, Québec, Canada., Zhang XM; Medical Development, Diabetes Business Unit, Eli Lilly Canada Inc, Toronto, Ontario, Canada., Rabasa-Lhoret R; Montreal Clinical Research Institute, Montreal, Québec, Canada., Tsoukas GM; McGill University Health Center, Montreal, Québec, Canada., Conway JR; Canadian Centre for Research on Diabetes, Smiths Falls, Ontario, Canada., Weisnagel SJ; CHU de Québec-Université Laval, Quebec City, Québec, Canada., Gerety G; Division of Community Endocrinology, Albany Medical College, Albany, New York., Woo VC; University of Manitoba, Winnipeg, Manitoba, Canada., Zhang S; Statistics, Eli Lilly and Company, Indianapolis, Indiana., Carballo D; Locemia Solutions, Montreal, Québec, Canada., Pradhan S; Global Scientific Communications, Diabetes Business Unit, Eli Lilly Services India Pvt. Ltd, Bangalore, India., Piché CA; Locemia Solutions, Montreal, Québec, Canada., Guzman CB; Medical Development, Diabetes Business Unit, Formerly Eli Lilly and Company, Indianapolis, Indiana. |
| المصدر: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 May; Vol. 20 (5), pp. 1316-1320. Date of Electronic Publication: 2018 Mar 22. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Wiley-Blackwell, c1999- |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 1/*drug therapy , Glucagon/*administration & dosage , Hypoglycemia/*drug therapy , Hypoglycemic Agents/*adverse effects , Insulin/*adverse effects, Administration, Intranasal ; Adult ; Blood Glucose/analysis ; Blood Glucose Self-Monitoring ; Caregivers ; Female ; Glucagon/therapeutic use ; Health Knowledge, Attitudes, Practice ; Humans ; Hypoglycemia/blood ; Hypoglycemia/chemically induced ; Hypoglycemia/physiopathology ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Lost to Follow-Up ; Male ; Middle Aged ; Patient Dropouts ; Patient Education as Topic ; Self Report ; Severity of Illness Index ; Syncope/etiology ; Syncope/prevention & control ; Time Factors |
| مستخلص: | In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D). Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time. Questionnaires were used to collect information about adverse events and ease of use of NG. In the efficacy analysis population, 69 patients experienced 157 HEs. In 95.7% patients, HEs resolved within 30 minutes of NG administration. In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help. Most caregivers reported that NG was easy to use. Most adverse events were local and of low to moderate severity. In this study, a single, 3-mg dose of NG demonstrated real-life effectiveness in treating moderate and severe HEs in adults with T1D. NG was well tolerated and easy to use. (© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.) |
| References: | Diabetes Care. 2017 Jan;40(1):155-157. (PMID: 27872155) Diabetes. 2014 May;63(5):1738-47. (PMID: 24757202) Diabetes Care. 2016 Apr;39(4):555-62. (PMID: 26884472) Diabet Med. 2010 Jan;27(1):72-8. (PMID: 20121892) Diabetes Care. 1995 Apr;18(4):517-22. (PMID: 7497862) J Diabetes Sci Technol. 2015 Jan;9(1):38-43. (PMID: 25385946) Diabetes Care. 2016 Feb;39(2):264-70. (PMID: 26681725) Diabetes Care. 2017 Dec;40(12):1641-1643. (PMID: 29162584) N Engl J Med. 2012 Sep 20;367(12):1108-18. (PMID: 22992074) Diabetes. 2010 Oct;59(10):2333-9. (PMID: 20876723) Pediatr Diabetes. 2018 Aug;19(5):1007-1013. (PMID: 29512902) Endocrinol Metab Clin North Am. 2010 Sep;39(3):641-54. (PMID: 20723825) Diabetes Technol Ther. 2017 Jul;19(7):423-432. (PMID: 28556672) Diabetes Obes Metab. 2018 May;20(5):1316-1320. (PMID: 29504662) Diabetes Metab Syndr Obes. 2011;4:337-46. (PMID: 21969805) |
| فهرسة مساهمة: | Keywords: adults; hypoglycaemia; nasal glucagon; type 1 diabetes |
| المشرفين على المادة: | 0 (Blood Glucose) 0 (Hypoglycemic Agents) 0 (Insulin) 9007-92-5 (Glucagon) |
| تواريخ الأحداث: | Date Created: 20180306 Date Completed: 20190114 Latest Revision: 20210109 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5947579 |
| DOI: | 10.1111/dom.13278 |
| PMID: | 29504662 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.13278 |